There are a few angles through which to view Tuesday’s acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals, but let’s start positively.
A buyout deal is happening in biotech, which is struggling mightily right now. Granted, this takeout is not a blockbuster — Regeneron is paying $250 million in cash to acquire Checkmate — but any deal at this point should help boost sentiment in a sector that has been abandoned by investors in 2022.
Optically, the purchase premium looks impressive. Checkmate is being acquired for $10.50 per share, or more than four times Monday’s closing price of $2.43. Regeneron isn’t a charity, so it’s not paying a super-premium just to be nice. This suggests that the biotech bear market, as painful as it is, has probably depressed valuations for certain companies far below fair value.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
